Investors

Press Releases

Press Releases

July 19, 2018

SAN CARLOS, Calif. , July 19, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. , (Nasdaq:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various eosinophil and mast cell related diseases, today announced the pricing of its initial public offering of

Copyright Nasdaq. Minimum 15 minutes delayed.